Home Cart Sign in  
Chemical Structure| 571190-30-2 Chemical Structure| 571190-30-2

Structure of Palbociclib
CAS No.: 571190-30-2

Chemical Structure| 571190-30-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Palbociclib is a highly specific inhibitor of Cdk4 and Cdk6 with IC50s of 11 nM and16 nM.

Synonyms: PD 0332991

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations      Show More

Ramponi, Valentina ; Richart, Laia ; Kovatcheva, Marta ; Stephan-Otto Attolini, Camille ; Capellades, Jordi ; Lord, Alice E , et al.

Abstract: Anti-cancer therapies can induce cellular senescence or drug-tolerant persistence, two types of proliferative arrest that differ in their stability. While senescence is highly stable, persistent cells efficiently resume proliferation upon therapy termination resulting in tumor relapse. Here, we used mTOR/PI3K inhibition to develop and characterize a model of persistence-associated proliferative arrest in human cancer cells of various origins. This allowed us to compare the same cancer cell lines under the two types of proliferative arrest. Persister and senescent cancer cells shared an expanded lysosomal compartment and hypersensitivity to BCL-XL inhibition. However, persister cells lacked other features of senescence, such as loss of lamin B1, senescence-associated β-galactosidase activity, upregulation of MHC-I, and an inflammatory and secretory phenotype (SASP). Genome-wide CRISPR/Cas9 screening for genes required for the survival of persister cells revealed that they are hypersensitive to the inhibition of one-carbon (1C) metabolism, which was validated by the pharmacological inhibition of SHMT, a key enzyme that feeds methyl groups from into 1C metabolism. By investigating the relationship between 1C metabolism and the epigenetic regulation of transcription, we found that the repressive heterochromatic mark H4K20me3 was enriched at the promoters of SASP and interferon response genes in persister cells, while it was absent in senescent cells. Moreover, persister cells overexpressed the H4K20 methyltransferases KMT5B/C, and their downregulation unleashed inflammatory programs and compromised the survival of persister cells. In summary, this study defined distinctive features of persister cancer cells, identified actionable vulnerabilities, and provided mechanistic insight into their low inflammatory activity.

Purchased from AmBeed:

Protasoni, Margherita ; López-Polo, Vanessa ; Stephan-Otto Attolini, Camille ; Brandariz, Julian ; Herranz, Nicolas ; Mateo, Joaquin , et al.

Abstract: Senescent cells play a causative role in many diseases, and their elimination is a promising therapeutic strategy. Here, through a genome-wide CRISPR/Cas9 screen, we identify the gene PPIF, encoding the mitochondrial protein cyclophilin D (CypD), as a novel senolytic target. Cyclophilin D promotes the transient opening of the mitochondrial permeability transition pore (mPTP), which serves as a failsafe mechanism for calcium efflux. We show that senescent cells exhibit a high frequency of transient CypD/mPTP opening events, known as 'flickering'. Inhibition of CypD using genetic or pharmacologic tools, including , leads to the toxic accumulation of mitochondrial Ca2+ and the death of senescent cells. Genetic or pharmacological inhibition of NCLX, another mitochondrial calcium efflux channel, also leads to senolysis, while inhibition of the main Ca2+ influx channel, MCU, prevents senolysis induced by CypD inhibition. We conclude that senescent cells are highly vulnerable to elevated mitochondrial Ca2+ ions, and that transient CypD/mPTP opening is a critical adaptation mechanism for the survival of senescent cells.

Keywords: Cellular Senescence ; ; Senolytic Therapy ; Cyclophilin D ; Flickering

Purchased from AmBeed:

Alternative Products

Product Details of Palbociclib

CAS No. :571190-30-2
Formula : C24H29N7O2
M.W : 447.53
SMILES Code : O=C1C(C(C)=O)=C(C)C2=CN=C(NC3=NC=C(N4CCNCC4)C=C3)N=C2N1C5CCCC5
Synonyms :
PD 0332991
MDL No. :MFCD11840850
InChI Key :AHJRHEGDXFFMBM-UHFFFAOYSA-N
Pubchem ID :5330286

Safety of Palbociclib

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H319-H372-H410
Precautionary Statements:P501-P273-P260-P270-P264-P280-P391-P314-P337+P313-P305+P351+P338-P301+P312+P330
Class:9
UN#:3077
Packing Group:

Related Pathways of Palbociclib

Hedgehog

Isoform Comparison

Biological Activity

Description
Palbociclib (PD 0332991) is an orally active, selective inhibitor of CDK4 and CDK6, showing IC50 values of 11 nM and 16 nM respectively. It exhibits strong anti-proliferative properties and is capable of inducing cell cycle arrest in cancer cells. This makes it a valuable agent in the study of HR-positive and HER2-negative breast cancer as well as hepatocellular carcinoma[1].[3].[4].
Target
  • CDK4

    CDK4/CyclinD1, IC50:11 nM

    CDK4/CyclinD3, IC50:9 nM

  • CDK6

    CDK6/CyclinD2, IC50:15 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
KPC1 PDAC cells 500 nM 8 days Induced cellular senescence and evaluated SASP-related gene expression PMC10516132
KPC2 PDAC cells 500 nM 8 days Induced cellular senescence and evaluated SASP-related gene expression PMC10516132
CHL-1 0.5 μM 24 h Palbociclib induced G0/G1 cell cycle arrest but did not lead to cell death. PMC5026598
A375 0.5 μM 24 h Palbociclib induced G0/G1 cell cycle arrest but did not lead to cell death. PMC5026598
C4–2b cells 100 nM and 1 μM 48 h To evaluate the effects of Palbociclib on prostate cancer cell growth, the results showed that Palbociclib combined with Olaparib significantly inhibited cell growth and induced apoptosis. PMC8456452
C4–2b-ENZR cells 100 nM and 1 μM 48 h To evaluate the effects of Palbociclib on enzalutamide-resistant prostate cancer cells, the results showed that Palbociclib combined with Olaparib significantly inhibited cell growth and induced apoptosis. PMC8456452
NCI-H660 cells 100 nM and 1 μM 48 h To evaluate the effects of Palbociclib on neuroendocrine prostate cancer cells, the results showed that Palbociclib combined with Olaparib significantly inhibited cell growth and induced apoptosis. PMC8456452
MCF-7 1–100nM 1 h Palbociclib significantly increased radiosensitivity in MCF-7 cells, with a radiation enhancement ratio (rER) of 1.15–1.67. PMC7744368
T47D 1–100nM 1 h Palbociclib significantly increased radiosensitivity in T47D cells, with a radiation enhancement ratio (rER) of 1.12–1.65. PMC7744368
MCF-7 500 nM 48 h To study the effect of Palbociclib on MCF-7 cells, results showed that Palbociclib could inhibit cell proliferation. PMC7425060
MCF-7 PalbR 500 nM 48 h To study the effect of Palbociclib on MCF-7 PalbR cells, results showed that Palbociclib could inhibit cell proliferation and induce cellular senescence. PMC7425060
SK-MEL-103 cells 2 μM 1 week Induced cellular senescence and increased expression of lysosomal membrane proteins LAMP1 and LAMP2 PMC9577959
Huh7 cells 2 μM 1 week Induced cellular senescence and increased expression of lysosomal membrane proteins LAMP2A, GBA, and CTSD PMC9577959
U2OS cells 2 μM 1 week Induced cellular senescence and increased expression of lysosomal membrane proteins LAMP2A, GBA, and CTSD PMC9577959
human fibroblasts 1 μM 10 days Induced cellular senescence, observed changes in cell size PMC6386581
RPE-1 cells 1 μM 16 h To synchronize cells at the G1/S transition and study DNA damage levels post-tetraploidization. PMC8986533

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Pancreatic cancer transplant model Oral 100 mg/kg 4 consecutive days followed by 3 days off treatment for 2 weeks Evaluated the effect of Palbociclib combined with Trametinib on tumor growth and immune response in pancreatic cancer PMC10516132
Mice 1205Lu xenograft model Oral 429 mg/kg Once daily for 51 days Palbociclib monotherapy initially suppressed 1205Lu tumor growth in vivo but progressive growth ensued. PMC5026598
male nude mice C4–2b-ENZR and NCI-H660 xenograft models oral gavage 100 mg/kg 5 days each week, for 15 days (C4–2b-ENZR model) or 21 days (NCI-H660 model) To evaluate the effects of Palbociclib combined with Olaparib on tumor growth in prostate cancer xenograft models, the results showed that the combination treatment significantly inhibited tumor growth and induced tumor cell apoptosis. PMC8456452
CB17-SCID mice MCF-7 xenograft model Oral 25mg/kg Once daily for 6 days Palbociclib combined with radiation significantly suppressed tumor growth and prolonged time to tumor doubling. PMC7744368
Mice Patient-derived xenograft (PDX) model Oral 100 mg/kg 5 days a week for 60 days To study the effect of Palbociclib on ER-positive breast cancer in vivo, results showed that Palbociclib could significantly inhibit tumor growth. PMC7425060

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03007979 Breast Cancer ... More >> Breast Carcinoma Cancer of Breast Malignant Tumor of Breast Less << Phase 2 Recruiting June 30, 2021 United States, Missouri ... More >> Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Cynthia X Ma, M.D., Ph.D.    314-362-9383    cynthiaxma@wustl.edu    Principal Investigator: Cynthia X Ma, M.D., Ph.D.          Sub-Investigator: Foluso O Ademuyiwa, M.D.          Sub-Investigator: Ron Bose, M.D., Ph.D.          Sub-Investigator: Mathew Cherian, M.D.          Sub-Investigator: Ashley Frith, M.D.          Sub-Investigator: Leonel Hernandez Aya, M.D.          Sub-Investigator: Peter Oppelt, M.D.          Sub-Investigator: Haeseong Park, M.D.          Sub-Investigator: Caron Rigden, M.D.          Sub-Investigator: Rama Suresh, M.D.          Sub-Investigator: Katherine Weilbaecher, M.D.          Sub-Investigator: Rebecca Aft, M.D., Ph.D.          Sub-Investigator: Lindsay Peterson, M.D.          United States, Nebraska University of Nebraska Recruiting Lincoln, Nebraska, United States, 68588 Contact: Jairam Krishnamurthy, M.D.    402-559-1800    jairam.krishnamurthy@unmc.edu    Principal Investigator: Jairam Krishnamurthy, M.D.          Sub-Investigator: Kenneth Cowan, M.D.          Sub-Investigator: Elizabeth Reed, M.D.          Sub-Investigator: Pavankumar Tandra, M.D. Less <<
NCT01907607 Advanced Gastrointestinal Stro... More >>mal Tumors Less << PHASE2 COMPLETED 2025-02-19 Institut Bergonié, Bordeaux, G... More >>ironde, 33076, France|Centre Georges-Francois Leclerc, Dijon, 21079, France|Centre Oscar Lambret, Lille, 59020, France|Centre Léon Bérard, Lyon, 69373, France|H?pital de la Timone - AP-HM, Marseille, 13385, France|Centre René Gauducheau, Nantes, 44805, France|H?pital Saint-Antoine (AP-HP), Paris, 75571, France|CHU de REIMS - H?pital Robert Debré, Reims, 51092, France|Institut Gustave Roussy, Villejuif, 94800, France Less <<
NCT03304080 Breast Neoplasms ... More >> Breast Diseases Less << Phase 1 Phase 2 Recruiting November 1, 2019 United States, New York ... More >> Mount Sinai Beth Israel Comprehensive Cancer Center West Recruiting New York, New York, United States, 10011 Contact: Paula Klein, MD    212-604-6021    paula.klein@mountsinai.org    Perlmutter Cancer Center NYU Langone Not yet recruiting New York, New York, United States, 10016 Contact: Sylvia Adams, MD    212-731-5795    sylvia.adams@nyumc.org    Sub-Investigator: Sylvia Adams, MD          Mount Sinai West Recruiting New York, New York, United States, 10019 Contact: Krystal Cascetta, MD    212-523-8692    krystal.cascetta@mountsinai.org    New York Presbyterian Herbert Irving Comprehensive Cancer Center at Columbia University Not yet recruiting New York, New York, United States, 10032 Contact: Kevin Kalinsky, MD    212-305-1945    Kk2693@columbia.edu    New York Presbyterian Meyer Cancer Center at Weill Cornell Not yet recruiting New York, New York, United States, 10065 Contact: Eleni Andreopoulou, MD    646-962-9888    ela9082@med.cornell.edu Less <<
NCT02778685 Estrogen Receptor Positive ... More >> HER2/Neu Negative Postmenopausal Recurrent Breast Carcinoma Stage IV Breast Cancer Less << Phase 2 Recruiting February 2019 United States, California ... More >> City of Hope Corona Recruiting Corona, California, United States, 92879 Contact: Cheryl Corpus    626-256-4673 ext 81529       Sub-Investigator: Misagh Karimi, MD          City of Hope Medical Center Recruiting Duarte, California, United States, 91010 Contact: Yuan Yuan, MD, PhD    800-826-4673       Principal Investigator: Yuan Yuan, MD, PhD          City of Hope Antelope Valley Recruiting Lancaster, California, United States, 93534 Contact: Regan Johnson    626-256-4673 ext 25648       Sub-Investigator: Mohammad Fekrazad, MD          City of Hope Mission Hills Recruiting Mission Hills, California, United States, 91345 Contact: Amy Shousha    626-256-4673 ext 81865       Sub-Investigator: Suzy Melkonian, MD          City of Hope Rancho Cucamonga Recruiting Rancho Cucamonga, California, United States, 91730 Contact: Valerie Estala    626-256-4673 ext 81699       Sub-Investigator: Behnam Ebrahimi, MD          City of Hope South Pasadena Recruiting South Pasadena, California, United States, 91030 Contact: Odessa Rodriguez    626-256-4673 ext 81409       Sub-Investigator: Christina Yeon, MD          City of Hope West Covina Recruiting West Covina, California, United States, 91790 Contact: Mei Zheng    626-256-4673 ext 81336       Sub-Investigator: Gargi Upadhyaya, MD Less <<
NCT02059330 Healthy Phase 1 Completed - United States, Connecticut ... More >> Pfizer Investigational Site New Haven, Connecticut, United States, 06511 Less <<
NCT01701375 Relapsed Acute Leukemia|Refrac... More >>tory Acute Leukemia|High-Risk Myelodysplasia Less << PHASE1 TERMINATED 2025-04-13 Sidney Kimmel Comprehensive Ca... More >>ncer Center at Johns Hopkins, Baltimore, Maryland, 21287, United States|Weill Cornell Medical Center, New York, New York, 10065, United States Less <<
NCT02536742 Metastatic Breast Cancer Phase 2 Recruiting January 2020 Belgium ... More >> Sint-Augustinus Recruiting Antwerpen, Belgium, 2610 Contact: Luc Dirix       cto@gza.be    Principal Investigator: Luc Dirix          Institut Jules Bodet Recruiting Brussels, Belgium, 1000 Contact: Michail Ignatiadis       michail.ignatiadis@bordet.be    Principal Investigator: Michail Ignatiadis          Cliniques Universitaires Saint-Luc Recruiting Brussels, Belgium, 1200 Contact: Francois Duhoux       francois.duhoux@uclouvain.be    Principal Investigator: Francois Duhoux          Antwerp University Hospital Recruiting Edegem, Belgium, 2650 Contact: Konstantinos Papadimitriou          Principal Investigator: Konstantinos Papadimitriou          UZ Leuven Recruiting Leuven, Belgium Contact: Patrick Neven          Principal Investigator: Patrick Neven          CHU Liege Recruiting Liège, Belgium Contact: Guy Jerusalem       g.jerusalem@chu.ulg.ac.be    Principal Investigator: Guy Jerusalem          Clinique St. Elizabeth Recruiting Namur, Belgium, 5000 Contact: Peter Vuylsteke       peter.vuylsteke@cmsenamur.be    Principal Investigator: Peter Vuylsteke          Italy Ospedali degli Infermi, S.O.C. Oncologia Recruiting Biella, Italy, 13879 Contact: Elena Seles, MD       seles.e@libero.it    Principal Investigator: Elena Seles, MD          Ospedale Centrale Bolzano, Medical Oncology Recruiting Bolzano, Italy Contact: Claudio Graiff       claudio.graiff@sabes.it    Principal Investigator: Claudio Graiff          IRCCS San Martino University Hospital Not yet recruiting Genova, Italy Contact: Alberto Ballestrero       aballestrero@unige.it    Principal Investigator: Alberto Ballestrero          Mater Salutis Hospital AULSS 21 della Regione Veneto Recruiting Legnago, Italy Contact: Andrea Bonetti       andrea.bonetti@aulsslegnago.it    Principal Investigator: Andrea Bonetti          Istituto Europeo di Oncologia Recruiting Milano, Italy Contact: Marco Colleoni       marco.colleoni@ieo.it    Principal Investigator: Marco Colleoni          Istituti Clinici Scientifici Maugeri, Medical Oncology Unit Recruiting Pavia, Italy, 27100 Contact: Antonio Bernardo       antonio.bernardo@icsmaugeri.it    Principal Investigator: Antonio Bernardo, MD          Azienda USL4 Prato Recruiting Prato, Italy Contact: Luca Malorni       lmalorni@usl4.toscana.it    Principal Investigator: Luca Malorni, MD PhD          United Kingdom UH Bristol NHS Foundation Trust Not yet recruiting Bristol, United Kingdom Principal Investigator: Jeremy Braybrooke          Velindre NHS Trust Not yet recruiting Cardiff, United Kingdom Principal Investigator: Jacinta Abraham          Western General Hospital Not yet recruiting Edinburgh, United Kingdom Principal Investigator: Dave Cameron          Beatson West of Scotland Cancer Centre Not yet recruiting Glasgow, United Kingdom Principal Investigator: Iain Macpherson          Singleton Hospital Not yet recruiting Swansea, United Kingdom Principal Investigator: Gianfilippo Bertelli          Royal Cornwall Not yet recruiting Truro, United Kingdom Principal Investigator: Alastair Thomson Less <<
NCT02142868 - - - -
NCT01701375 Relapsed Acute Leukemia|Refrac... More >>tory Acute Leukemia|High-Risk Myelodysplasia Less << PHASE1 TERMINATED 2025-04-13 Sidney Kimmel Comprehensive Ca... More >>ncer Center at Johns Hopkins, Baltimore, Maryland, 21287, United States|Weill Cornell Medical Center, New York, New York, 10065, United States Less <<
NCT02760030 Estrogen Receptor and/or Proge... More >>sterone Receptor Positive HER2/Neu Negative Stage IA Breast Cancer Stage IB Breast Cancer Stage IIA Breast Cancer Stage IIB Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Less << Phase 2 Recruiting - United States, Ohio ... More >> Ohio State University Comprehensive Cancer Center Recruiting Columbus, Ohio, United States, 43210 Contact: Megan Laibach Thomason    614-366-0115    Megan.Laibachthompson@osumc.edu    Principal Investigator: Nicole Williams Less <<
NCT03377101 Estrogen Receptor Positive ... More >> HER2/Neu Negative Progesterone Receptor Positive Stage IV Breast Cancer AJCC v6 and v7 Less << Phase 2 Withdrawn(change in study desi... More >>gn.) Less << - -
NCT02764541 Breast Cancer Phase 2 Recruiting November 2019 United States, Connecticut ... More >> Stamford Hospital Recruiting Stamford, Connecticut, United States, 06904 Contact: K.M. Steve Lo, MD       slo@stamhealth.org    United States, Maine Eastern Maine Medical Center Recruiting Brewer, Maine, United States, 04412 Contact: Thomas H. Openshaw, MD       topenshaw@emhs.org    United States, Massachusetts Dana-Farber at St. Elizabeth's Medical Center Recruiting Boston, Massachusetts, United States, 02135 Contact: Caroline Block, MD       caroline_block@dfci.harvard.edu    Beth Israel Deaconess Medical Center Recruiting Boston, Massachusetts, United States, 02215 Contact: Steven Come, MD    617-667-4599    scome@bidmc.harvard.edu    Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Otto F Metzger, MD    617-632-3800    ometzger@partners.org    Principal Investigator: Otto F Metzger, MD          DF/BWCC at Milford Regional Medical Center Recruiting Milford, Massachusetts, United States, 01757 Contact: Michael Constantine, MD       michael_constantine@dfci.harvard.edu    DF/BWCC in clinical affiliation with South Shore Hospital Recruiting South Weymouth, Massachusetts, United States, 02190 Contact: Meredith Faggen, MD       meredith_faggen@dfci.harvard.edu    United States, Rhode Island Lifespan Recruiting Providence, Rhode Island, United States, 02903 Contact: Mary Anne Fenton, MD       mfenton@lifespan.org    United States, Tennessee Sarah Cannon Research Institute Recruiting Nashville, Tennessee, United States, 37203 Contact: Denise A. Yardley, MD       dyardley@tnonc.com    Vanderbilt University Medical Center Recruiting Nashville, Tennessee, United States, 37232 Contact: Ingrid Mayer, MD       ingrid.mayer@vanderbilt.edu Less <<
NCT02041273 Healthy Phase 1 Completed - United States, Connecticut ... More >> Pfizer Investigational Site New Haven, Connecticut, United States, 06511 Less <<
NCT02692755 Hormone Receptor Positive HER-... More >>2 Negative Breast Cancer Less << Phase 2 Phase 3 Recruiting December 2019 United States, District of Col... More >>umbia MedStar Georgetown University Hospital Recruiting Washington, District of Columbia, United States, 20007 Contact: Nellie Novielli, RN    202-784-3923    noviella@georgetown.edu    Contact: Julie Castle, RN    2026872209    bickmorj@georgetown.edu    Principal Investigator: Filipa Lynce, MD          MedStar Washington Hospital Center Recruiting Washington, District of Columbia, United States, 20013 Contact: Gouled Ahmed    202-877-9374    Gouled.A.Ahmed@medstar.net    Principal Investigator: Christopher Gallagher          United States, Illinois University of Chicago Recruiting Chicago, Illinois, United States, 60637 Contact: Simona Olberkyte    773-834-9114    solberkyte@medicine.bsd.uchicago.edu    Principal Investigator: Olwen Hahn, MD          United States, Maryland MedStar Union Memorial Hospital Recruiting Baltimore, Maryland, United States, 21218 Contact: Barbara Rector    410-261-8151       Principal Investigator: Mahsa Mohebtash, MD          MedStar Good Samaritan Hospital Recruiting Baltimore, Maryland, United States, 21239 Contact: Barbara Rector    410-261-8151       Principal Investigator: Lois Kamugisha, MD          United States, Pennsylvania Thomas Jefferson University Recruiting Philadelphia, Pennsylvania, United States, 19107 Contact: Rita Murphy    215-955-9626    Rita.murphy@jefferson.edu    Principal Investigator: Maysa Abu-Khalaf, MD Less <<
NCT02065063 Cancer Phase 1 Completed - United States, Massachusetts ... More >> GSK Investigational Site Boston, Massachusetts, United States, 02114 United States, Tennessee GSK Investigational Site Nashville, Tennessee, United States, 37232 United States, Texas GSK Investigational Site Houston, Texas, United States, 77030-4009 Less <<
NCT01976169 Advanced Breast Cancer Phase 1 Recruiting December 2020 United States, Texas ... More >> UT Southwestern Medical Center Recruiting Dallas, Texas, United States, 75390 Contact: Barbara Haley, MD    214-648-4180    barbara.haley@utsouthwestern.edu    Contact: Gregg Wright    214-648-7097    James.Wright@UTSouthwestern.edu    Sub-Investigator: Dawn Klemow, MD          Sub-Investigator: Erik Knudsen, MD          Sub-Investigator: Navid Sadeghi, MD          Sub-Investigator: Lori Watumull, MD          Principal Investigator: Barbara Haley, MD Less <<
NCT03065387 Malignant Neoplasm of Breast ... More >> Malignant Neoplasms of Digestive Organs Malignant Neoplasms of Female Genital Organs Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites Malignant Neoplasms of Independent (Primary) Multiple Sites Malignant Neoplasms of Lip Oral Cavity and Pharynx Malignant Neoplasms of Mesothelial and Soft Tissue Malignant Neoplasms of Respiratory and Intrathoracic Organs Malignant Neoplasms of Thyroid and Other Endocrine Glands Malignant Neoplasms of Urinary Tract Neoplasms of Uncertain or Unknown Behavior Less << Phase 1 Recruiting October 2023 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact       spihapau@mdanderson.org Less <<
NCT01918176 Healthy Phase 1 Completed - United States, Florida ... More >> Pfizer Investigational Site South Miami, Florida, United States, 33143 Less <<
NCT02592746 Metastatic Breast Cancer Phase 2 Recruiting June 2021 Korea, Republic of ... More >> Samsung Medical Center Not yet recruiting Seoul, Korea, Republic of, 135-710 Contact: Yeon-Hee Park, MD, Ph.D    82-2-3410-1780    yeonh.park@samsung.com    Samsung Medical Center Recruiting Seoul, Korea, Republic of Contact: Yeon Hee Park Less <<
NCT02222441 Healthy Phase 1 Completed - United States, Connecticut ... More >> New Haven Clinical Research Unit New Haven, Connecticut, United States, 06511 Less <<
NCT02785939 CCND1 Gene Amplification ... More >> CCND2 Gene Amplification CCND3 Gene Amplification CDK4 Gene Amplification Recurrent Squamous Cell Lung Carcinoma Stage IV Squamous Cell Lung Carcinoma AJCC v7 Less << Phase 2 Phase 3 Active, not recruiting April 1, 2022 -
NCT03079011 Metastatic Breast Cancer Phase 3 Recruiting April 15, 2024 France ... More >> Centre Leon Berard Not yet recruiting Lyon, France Contact: Thomas BACELOT, MD - PhD    + 33 (0)4 78 78 26 54    thomas.bachelot@lyon.unicancer.fr    Principal Investigator: Thomas Bachelot, MD - PhD          Institut Curie Recruiting Paris, France, 75005 Contact: François-Clément BIDARD, MD- PhD    + 33 (0)1 44 32 40 00    fcbidard@curie.fr    Principal Investigator: François-Clément BIDARD, MD - PhD          Gustave Roussy Not yet recruiting Villejuif, France, 94805 Contact: Suzette DELALOGE, MD    + 33 (0)1 42 11 42 93    Suzette.Delaloge@gustaveroussy.fr    Principal Investigator: Suzette DELALOGE, MD Less <<
NCT02499146 Advanced Breast Cancer Phase 1 Active, not recruiting January 26, 2020 China, Beijing ... More >> Beijing Cancer Hospital/Oncology department Beijing, Beijing, China, 100142 China, Guangdong Sun Yat-Sen University Cancer Center Guangzhou, Guangdong, China, 510060 Guangdong General Hospital/Department of Breast Surgery Guangzhou, Guangdong, China, 510080 China, Heilongjiang Harbin Medical University Cancer Hospital Harbin, Heilongjiang, China, 150081 China, Jilin The first hospital of jilin university Changchun, Jilin, China, 130021 China, Zhejiang The First Affiliated Hospital of College of Medicine, Zhejiang University Hangzhou, Zhejiang, China, 310003 China Cancer Institute and Hospital, Chinese Academy of Medical Sciences Beijing, China, 100021 Less <<
NCT02297438 Breast Neoplasms Phase 3 Active, not recruiting December 2, 2022 -
NCT01536743 Ovarian Epithelial Carcinoma Phase 2 Active, not recruiting May 10, 2020 United States, California ... More >> Jonsson Comprehensive Cancer Center at UCLA Los Angeles, California, United States, 90095 Less <<
NCT01227434 Glioblastoma ... More >>Gliosarcoma Anaplastic Astrocytoma Less << Phase 2 Terminated - United States, California ... More >> University of California, San Francisco San Francisco, California, United States, 94143 Less <<
NCT03159195 - Recruiting September 30, 2019 United States, New York ... More >> Pfizer, Inc. Recruiting New York, New York, United States, 10017 Less <<
NCT01227434 - Terminated - -
NCT02871791 Human Epidermal Growth Factor ... More >>2 Negative Carcinoma of Breast Hormone Receptor (HR)-Positive Breast Cancer Less << Phase 1 Phase 2 Recruiting July 2021 United States, Massachusetts ... More >> Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Sara Tolaney, MD, MPH    617-632-2335    stolaney@partners.org    Principal Investigator: Sara Tolaney, MD, MPH Less <<
NCT03709082 HER2-positive Breast Cancer ... More >> Breast Cancer Metastatic Less << Phase 1 Phase 2 Recruiting October 15, 2025 United States, Kansas ... More >> The University of Kansas Cancer Center, West Clinic Recruiting Kansas City, Kansas, United States, 66112 Contact: Clinical Trials Nurse Navigator    913-945-7552    ctnursenav@kumc.edu    The University of Kansas Cancer Center, Westwood Campus Recruiting Kansas City, Kansas, United States, 66205 Contact: Clinical Trials Nurse Navigator    913-945-7552    ctnursenav@kumc.edu    The University of Kansas Cancer Center, Overland Park Clinic Recruiting Overland Park, Kansas, United States, 66210 Contact: Clinical Trials Nurse Navigator    913-945-7552    ctnursenav@kumc.edu    United States, Missouri The University of Kansas Cancer Center, North Clinic Recruiting Kansas City, Missouri, United States, 64154 Contact: Clinical Trials Nurse Navigator    913-945-7552    ctnursenav@kumc.edu    The University of Kansas Cancer Center, Lee's Summit Clinic Recruiting Lee's Summit, Missouri, United States, 64064 Contact: Clinical Trials Nurse Navigator    913-945-7552    ctnursenav@kumc.edu Less <<
NCT01821066 Healthy Phase 1 Completed - United States, Connecticut ... More >> Pfizer Investigational Site New Haven, Connecticut, United States, 06511 Less <<
NCT02605486 Metastatic Breast Cancer (MBC) Phase 1 Phase 2 Recruiting November 2020 United States, New Jersey ... More >> Memoral Sloan Kettering Cancer Center Recruiting Basking Ridge, New Jersey, United States Contact: Ayca Gucalp, MD    646-888-4536       Memorial Sloan Kettering Monmouth Recruiting Middletown, New Jersey, United States, 07748 Contact: Ayca Gucalp, MD    646-888-4536       United States, New York Memorial Sloan Kettering Cancer Center @ Suffolk Recruiting Commack, New York, United States, 11725 Contact: Ayca Gucalp, MD    646-888-4536       Memorial Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Ayca Gucalp, MD    646-888-4536       Memorial Sloan Kettering at Mercy Medical Center Recruiting Rockville Centre, New York, United States Contact: Ayca Gucalp, MD    646-888-4536 Less <<
NCT02730429 Endometrial Cancer Phase 2 Recruiting December 2022 Denmark ... More >> NSGO Recruiting Copenhagen, Sjaelland, Denmark, 2100 Contact: Pernille Strøm, RN       pernille.stroem@regionh.dk Less <<
NCT02917005 Metastatic Breast Cancer Phase 2 Not yet recruiting March 2022 -
NCT02690480 Breast Neoplasms Phase 2 Recruiting December 2022 Ireland ... More >> Bon Secours Hospital Recruiting Cork, Ireland Beaumont Hospital Withdrawn Dublin, Ireland Mater Misericordiae University Hospital Recruiting Dublin, Ireland Mater Private Hospital Withdrawn Dublin, Ireland St. James´s Hospital Withdrawn Dublin, Ireland Galway University Hospital Recruiting Galway, Ireland University Hospital Limerick Withdrawn Limerick, Ireland University Hospital Waterford Recruiting Waterford, Ireland Spain Hospital Universitario Central de Asturias Recruiting Oviedo, Asturias, Spain, 33011 Hospital Universitari Son Espases Recruiting Palma de Mallorca, Baleares, Spain, 07120 Hospital Son Llàtzer Recruiting Palma De Mallorca, Baleares, Spain, 07198 Hospital Universitario Mutua Terrassa Recruiting Terrassa, Barcelona, Spain, 08221 Hospital Universitario Infanta Cristina Recruiting Parla, Madrid, Spain, 28981 Hospital Universitario Quirón de Madrid Recruiting Pozuelo de Alarcón, Madrid, Spain, 28223 Clínica Universidad de Navarra Withdrawn Pamplona, Navarra, Spain, 31008 Complejo Hospitalario Universitario Vigo Recruiting Vigo, Pontevedra, Spain, 36204 Hospital Universitario Sant Joan Reus Recruiting Reus, Tarragona, Spain, 43204 Centro Oncológico de Galicia Recruiting A Coruña, Spain, 15009 Hospital del Mar Recruiting Barcelona, Spain, 08003 Hospital de la Santa Creu y Sant Pau Recruiting Barcelona, Spain, 08026 Hospital Universitario Germans Trias i Pujol Recruiting Barcelona, Spain, 08916 Hospital Universitario Reina Sofía Recruiting Córdoba, Spain, 14004 Complejo Hospitalario de Jaén Recruiting Jaen, Spain, 23007 Complejo Asistencial Universitario de León Recruiting Leon, Spain, 24080 Hospital Universitario Ramón y Cajal Recruiting Madrid, Spain, 28034 Hospital Clínico Universitario San Carlos Recruiting Madrid, Spain, 28040 Hospital Universitario de Fuenlabrada Recruiting Madrid, Spain, 28492 Hospital Regional Universitario de Málaga Recruiting Málaga, Spain, 29011 Hospital Universitario Virgen de la Macarena Recruiting Sevilla, Spain, 41009 Hospital Quirón Sagrado Corazón de Sevilla Recruiting Sevilla, Spain, 41013 Hospital Universitario Vírgen del Rocío Recruiting Sevilla, Spain, 41013 Hospital Universitario de Valme Recruiting Sevilla, Spain, 41014 Hospital Clínico Universitario de Valencia Recruiting Valencia, Spain, 46010 Hospital General Universitario Valencia Recruiting Valencia, Spain, 46014 Hospital Universitario I Politècnic La Fe Recruiting Valencia, Spain, 46026 Hospital Universitario Miguel Servet Recruiting Zaragoza, Spain, 50009 Less <<
NCT01291017 Non-small Cell Lung Cancer Phase 2 Completed - United States, Florida ... More >> UF Health Cancer Center Gainesville, Florida, United States, 32610 H. Lee Moffitt Cancer and Research Institute Tampa, Florida, United States, 33612 Less <<
NCT02389842 Advanced Solid Tumours ... More >> Breast Cancer Less << Phase 1 Unknown August 2017 United Kingdom ... More >> The Royal Marsden NHS Foundation Trust Recruiting London, United Kingdom, SM2 5PT Contact: Timothy Yap, PhD    02086613539    timothy.yap@icr.ac.uk    Principal Investigator: Timothy Yap, PhD          The Christie NHS Foundation Trust Not yet recruiting Manchester, United Kingdom, M20 4BX Contact: Anne Amstrong, MBBS    0161 446 3746    elaine.mercer@christie.nhs.uk    Principal Investigator: Anne Armstrong, MBBS Less <<
NCT03573648 Breast Cancer Phase 2 Recruiting August 2020 United States, Maryland ... More >> Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Recruiting Baltimore, Maryland, United States, 21287 Contact: Hopkins Breast Trials       HopkinsBreastTrials@jhmi.edu    Contact: Kimmel Cancer Center Clinical Research Office    410-955-8866    jhcccro@jhmi.edu    Principal Investigator: Cesar A Santa-Maria, MD, MSCI Less <<
NCT03355157 Metastatic Breast Cancer Phase 4 Recruiting December 31, 2021 Germany ... More >> Agaplesion Markus Krankenhaus - Klinik für Gynäkologie und Geburtshilfe Recruiting Frankfurt am Main, Germany, 60431 Contact: Marc Thill, MD, PhD       marc.thill@fdk.info Less <<
NCT03147287 Metastatic Breast Cancer Phase 2 Recruiting December 31, 2024 United States, Maine ... More >> Eastern Maine Medical Center Recruiting Bangor, Maine, United States, 04401 Contact: Zarah Lucas, MD       zdlucas@emhs.org    United States, Massachusetts Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Erica L Mayer, MD MPH    617-632-2335    emayer@partners.org    Principal Investigator: Erica L. Mayer, MD MPH          Dana-Farber at St. Elizabeth's Medical Center Recruiting Brighton, Massachusetts, United States, 02135 Contact: Caroline Block, MD       caroline_block@dfci.harvard.edu    DF/BWCC at Milford Regional Medical Center Recruiting Milford, Massachusetts, United States, 01757 Contact: Michael Constantine, MD       michael_constantine@dfci.harvard.edu    DF/BWCC in clinical affiliation with South Shore Hospital Recruiting South Weymouth, Massachusetts, United States, 02190 Contact: Meredith Faggen, MD       meredith_faggen@dfci.harvard.edu    United States, Missouri Washington University Recruiting Saint Louis, Missouri, United States, 63110 Contact: Cynthia Ma, MD       cynthiaxma@wustl.edu    United States, New Hampshire Dana-Farber/New Hampshire Oncology-Hematology Recruiting Londonderry, New Hampshire, United States, 03053 Contact: Fred Briccetti, MD       fred_briccetti@dfci.harvard.edu Less <<
NCT03219554 Thymic Cancer PHASE2 UNKNOWN 2025-12-20 Samsung Medical Center, Seoul,... More >> 135-710, Korea, Republic of Less <<
NCT02942355 Female Breast Carcinoma Phase 2 Recruiting October 2022 United States, North Carolina ... More >> Levine Cancer Institute Recruiting Charlotte, North Carolina, United States, 28204 Contact: Wendy Vandermolen Less <<
NCT03471663 Breast Cancer Phase 1 Recruiting October 2020 United States, Colorado ... More >> Local Institution Recruiting Aurora, Colorado, United States, 80012 Contact: Site 105          United States, Tennessee Local Institution Recruiting Nashville, Tennessee, United States, 37203-1619 Contact: Site 102          United States, Texas Local Institution Recruiting Dallas, Texas, United States, 75246 Contact: Site 106          Local Institution Recruiting San Antonio, Texas, United States, 78217 Contact: Site 104          Local Institution Recruiting Tyler, Texas, United States, 75702 Contact: Site 103          United States, Washington Local Institution Recruiting Tacoma, Washington, United States, 98405-5093 Contact: Site 101 Less <<
NCT01291017 - Completed - -
NCT02040857 Breast Cancer Phase 2 Active, not recruiting June 2019 United States, California ... More >> University of California, San Francisco San Francisco, California, United States, 94115 United States, Indiana Indiana University Health Hospital Indianapolis, Indiana, United States, 46202 United States, Massachusetts Massachusetts General Hospital Boston, Massachusetts, United States, 02214 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 MGH/North Shore Cancer Center Danvers, Massachusetts, United States, 01923 DF/DWCC at Milford Regional Cancer Center Milford, Massachusetts, United States, 01757 South Shore Hospital Weymouth, Massachusetts, United States, 02190 United States, New Hampshire Dana-Farber/New Hampshire Oncology-Hematology Londonderry, New Hampshire, United States, 03053 United States, Pennsylvania University of Pennsylvania-Abramson Cancer Center Philadelphia, Pennsylvania, United States, 19104 Less <<
NCT03774472 Anatomic Stage I Breast Cancer... More >> AJCC v8 Anatomic Stage IA Breast Cancer AJCC v8 Anatomic Stage IB Breast Cancer AJCC v8 Anatomic Stage II Breast Cancer AJCC v8 Anatomic Stage IIA Breast Cancer AJCC v8 Anatomic Stage IIB Breast Cancer AJCC v8 Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage IIIA Breast Cancer AJCC v8 Anatomic Stage IIIB Breast Cancer AJCC v8 Anatomic Stage IIIC Breast Cancer AJCC v8 Anatomic Stage IV Breast Cancer AJCC v8 Estrogen Receptor Positive HER2/Neu Negative MKI67 Positive Postmenopausal Prognostic Stage I Breast Cancer AJCC v8 Prognostic Stage IA Breast Cancer AJCC v8 Prognostic Stage IB Breast Cancer AJCC v8 Prognostic Stage IIA Breast Cancer AJCC v8 Prognostic Stage IIB Breast Cancer AJCC v8 Prognostic Stage III Breast Cancer AJCC v8 Prognostic Stage IIIA Breast Cancer AJCC v8 Prognostic Stage IIIB Breast Cancer AJCC v8 Prognostic Stage IIIC Breast Cancer AJCC v8 Prognostic Stage IV Breast Cancer AJCC v8 Less << Phase 1 Phase 2 Recruiting December 31, 2019 United States, Texas ... More >> M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Debasish Tripathy    713-794-4385       Principal Investigator: Debasish Tripathy Less <<
NCT03024489 Head and Neck Cancer ... More >> Locally Advanced Unresectable Less << Phase 1 Phase 2 Recruiting December 2026 Thailand ... More >> Faculty of Medicine, Ramathibodi Hospital Recruiting Bangkok, Thailand, 10400 Contact: Somthawin Lukerak    +66-2-201-1671    somthawin.aie@mahidol.ac.th Less <<
NCT02679755 Breast Cancer Phase 4 Recruiting June 2019 Australia, New South Wales ... More >> Alexander David Guminski Recruiting North Sydney, New South Wales, Australia, 2060 Alexander Maxwell Menzies Recruiting North Sydney, New South Wales, Australia, 2060 Benjamin Carl Forster Recruiting North Sydney, New South Wales, Australia, 2060 Frances Mary Boyle Recruiting North Sydney, New South Wales, Australia, 2060 HPS Pharmacies - North Sydney Recruiting North Sydney, New South Wales, Australia, 2060 Mater Hospital Sydney Recruiting North Sydney, New South Wales, Australia, 2060 Royal North Shore Hospital - Clinical Trials Pharmacy Recruiting St Leonards, New South Wales, Australia, 2065 Royal North Shore Hospital Recruiting St Leonards, New South Wales, Australia, 2065 Pathology North-RNS Recruiting Sydney, New South Wales, Australia, 2065 Australia, Queensland Icon Cancer Care Wesley Recruiting Auchenflower, Queensland, Australia, 4066 River City Pharmacy Recruiting Auchenflower, Queensland, Australia, 4066 Icon Cancer Care Chermside Recruiting Chermside, Queensland, Australia, 4032 Haematology & Oncology Clinics of Australia Pty Ltd trading as Icon Cancer Care Corporate Office Recruiting South Brisbane, Queensland, Australia, 4101 Icon Cancer Care South Brisbane Recruiting South Brisbane, Queensland, Australia, 4101 Icon Cancer Foundation Recruiting South Brisbane, Queensland, Australia, 4101 Icon Cancer Care Southport Recruiting Southport, Queensland, Australia, 4215 Australia, South Australia Flinders Medical Centre-Pharmacy Department Recruiting Bedford Park, South Australia, Australia, 5042 Flinders Medical Centre Recruiting Bedford Park, South Australia, Australia, 5042 Australia, Victoria Monash Health-Parmacy Recruiting Clayton, Victoria, Australia, 3168 Monash Health Recruiting Clayton, Victoria, Australia, 3168 Peter MacCallum Cancer Centre Pharmacy Recruiting Melbourne, Victoria, Australia, 3000 Sunshine Hospital Pharmacy - Clinical Trials Recruiting St Albans, Victoria, Australia, 3021 Sunshine Hospital Recruiting St Albans, Victoria, Australia, 3021 Australia, Western Australia Fiona Stanley Hospital Recruiting Murdoch, Western Australia, Australia, 6150 Pharmacy Department Recruiting Murdoch, Western Australia, Australia, 6150 India Rajiv Gandhi Cancer Institute And Research Centre Recruiting New Delhi, Delhi, India, 110 085 Dr. B.R.A Institute Rotary Cancer Hospital, All India Institue of Medical Sciences Recruiting New Delhi, Delhi, India, 110029 The Gujarat Cancer & Research Institute Recruiting Ahmedabad, Gujarat, India, 380016 Manipal Hospital Recruiting Bangalore, Karnataka, India, 560017 HealthCare Global Enterprises Ltd. Recruiting Bangalore, Karnataka, India, 560027 Kasturba Hospital, Manipal Centre For Clinical Research Recruiting Manipal, Karnataka, India, 576104 Tata Memorial Centre, Tata Memorial Hospital Recruiting Mumbai, Maharashtra, India, 400 012 Meditrina Institute Of Medical Sciences Recruiting Nagpur, Maharashtra, India, 440012 Shatabdi Hospital Recruiting Nashik, Maharashtra, India, 422005 Deenanath Mangeshkar Hospital and Research Center Recruiting Pune, Maharashtra, India, 411 004 Sahyadri Speciality Hospital Recruiting Pune, Maharashtra, India, 411004 Apollo Speciality Hospital Recruiting Chennai, Tamilnadu, India, 600 035 Less <<
NCT03709680 Solid Tumors ... More >>Ewing Sarcoma Rhabdoid Tumor Rhabdomyosarcoma Neuroblastoma Medulloblastoma Less << Phase 1 Not yet recruiting September 27, 2023 -
NCT02897375 Solid Neoplasm ... More >> Stage III Pancreatic Cancer Stage IIIA Breast Cancer Stage IIIA Non-Small Cell Lung Cancer Stage IIIB Breast Cancer Stage IIIB Non-Small Cell Lung Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer Stage IV Non-Small Cell Lung Cancer Stage IVA Pancreatic Cancer Stage IVB Pancreatic Cancer Sarcoma Colorectal Cancer Head and Neck Cancer Cancer of Unknown Primary Bladder Cancer Ovarian Cancer Less << Phase 1 Recruiting December 2021 United States, Georgia ... More >> Emory University/Winship Cancer Institute Recruiting Atlanta, Georgia, United States, 30322 Contact: Nakita Brown    404-616-9850    nlbrown@emory.edu    Contact: Monique Williams    404-778-4383    monique.guyinn@emory.edu Less <<
NCT03560531 Breast Cancer Phase 1 Recruiting December 2020 United States, New York ... More >> Columbia University Medical Center Recruiting New York, New York, United States, 10032 United States, Texas Baylor College of Medicine Recruiting Houston, Texas, United States, 77030 Less <<
NCT02905318 Prostate Cancer PHASE2 ACTIVE_NOT_RECRUITING 2024-12-30 QEII Health Sciences Centre, H... More >>alifax, Nova Scotia, B3H 1V7, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, L8V 5C2, Canada|London Regional Cancer Program, London, Ontario, N6A 5W9, Canada|Odette Cancer Centre, Toronto, Ontario, M4N 3M5, Canada|University Health Network, Toronto, Ontario, M5G 2M9, Canada|CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, H2X 3E4, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, S4T 7T1, Canada Less <<
NCT02159755 CCND1 Positive ... More >> Recurrent Mantle Cell Lymphoma t(11;14) Less << Phase 1 Active, not recruiting - United States, Missouri ... More >> Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, New York Weill Medical College of Cornell University New York, New York, United States, 10065 United States, North Carolina UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States, 27599 United States, Ohio Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 Less <<
NCT02030483 Multiple Myeloma Phase 1 Terminated(The company providi... More >>ng one of the study drugs withdrew its support due to low enrollment. Therefore, we had to close the study due to lack of funding.) Less << - United States, New York ... More >> Weill Cornell Medical College New York, New York, United States, 10065 Less <<
NCT03423199 Breast Neoplasms Phase 3 Recruiting February 2022 Japan ... More >> Aichi Cancer Center Hospital Recruiting Nagoya, Aichi, Japan, 464-8681 Contact: Hiroji Iwata, MD          National Cancer Center Hospital East Recruiting Kashiwa, Chiba, Japan, 2778577 Contact: Hirofumi Mukai, MD, PhD          National Hospital Organization Shikoku Cancer Center Recruiting Matsuyama, Ehime, Japan, 7910280 Contact: Kenjiro Aogi          National Hospital Organization Hokkaido Cancer Center Recruiting Sapporo, Hokkaido, Japan, 0030804 Contact: Masato Takahashi, MD, PhD          Hyogo Cancer Center Recruiting Akashi, Hyogo, Japan, 6738558 Contact: Koji Matsumoto, MD          Kanagawa Cancer Center Recruiting Yokohama, Kanagawa, Japan, 2418515 Contact: Toshinari Yamashita, MD, PhD          Kindai University Hospital Recruiting Ōsaka-sayama, Osaka, Japan, 5898511 Contact: Junji Tsurutani, MD, PhD          Toranomon Hospital Recruiting Minato-Ku, Tokyo, Japan, 1058470 Contact: Toshimi Takano, MD          Chiba Cancer Center Recruiting Chiba, Japan, 2608717 Contact: Naohito Yamamoto, MD, PhD          Kyusyu Cancer Center Recruiting Fukuoka, Japan, 8111395 Contact: Eriko Tokunaga, MD          National Hospital Organization Osaka National Hospital Recruiting Osaka, Japan, 5400006 Contact: Norikazu Masuda          National Cancer Center Hospital Recruiting Tokyo, Japan, 104-0045 Contact: Kenji Tamura, MD, PhD          Korea, Republic of National Cancer Center Recruiting Gyeonggi-do, Korea, Republic of, 10408 Contact: Keun Seok Lee, MD, PhD          Ajou University Hospital Recruiting Gyeonggi-do, Korea, Republic of, 16499 Contact: Seok Yun Kang, MD          Seoul National University Bundang Hospital Recruiting Gyeonggi-do, Korea, Republic of, 463-707 Contact: Jee Hyun Kim, MD, MS, PhD          Seoul National University Hospital Recruiting Seoul, Korea, Republic of, 03080 Contact: Kyung-Hun Lee, MS, PhD          Asan Medical Center Recruiting Seoul, Korea, Republic of, 05505 Contact: Kyung Hae Jung, MD, PhD          Severance Hospital, Yonsei University Health System Recruiting Soeul, Korea, Republic of, 03722 Contact: Joo Hyuk Sohn, MD          Singapore National University Hospital Recruiting Singapore, Singapore, 119882 Contact: Soo Chin Lee, MMed, MRCP          National Cancer Centre Singapore Recruiting Singapore, Singapore, 169610 Contact: Yoon Sim Yap, MD          Taiwan National Taiwan University Hospital Recruiting Taipei, Taiwan, 10048 Contact: Yen-Shen Lu, PhD          Taipei Vetarans General Hospital Recruiting Taipei, Taiwan, 11217 Contact: Ling-Ming Tseng, MD          Sun Yat-Sen Cancer Center Recruiting Taipei, Taiwan, 11259 Contact: Mei-Ching Liu, MD Less <<
NCT03526250 Advanced Malignant Solid Neopl... More >>asm RB1 Positive Recurrent Childhood Ependymoma Recurrent Ewing Sarcoma Recurrent Glioma Recurrent Hepatoblastoma Recurrent Kidney Wilms Tumor Recurrent Langerhans Cell Histiocytosis Recurrent Malignant Germ Cell Tumor Recurrent Malignant Glioma Recurrent Medulloblastoma Recurrent Neuroblastoma Recurrent Non-Hodgkin Lymphoma Recurrent Osteosarcoma Recurrent Peripheral Primitive Neuroectodermal Tumor Recurrent Rhabdoid Tumor Recurrent Rhabdomyosarcoma Recurrent Soft Tissue Sarcoma Refractory Ependymoma Refractory Ewing Sarcoma Refractory Glioma Refractory Hepatoblastoma Refractory Langerhans Cell Histiocytosis Refractory Malignant Germ Cell Tumor Refractory Malignant Glioma Refractory Medulloblastoma Refractory Neuroblastoma Refractory Non-Hodgkin Lymphoma Refractory Osteosarcoma Refractory Peripheral Primitive Neuroectodermal Tumor Refractory Rhabdoid Tumor Refractory Rhabdomyosarcoma Refractory Soft Tissue Sarcoma Less << Phase 2 Recruiting March 30, 2023 -
NCT02774681 Breast Carcinoma Metastatic in... More >> the Brain Estrogen Receptor Negative HER2/Neu Negative HER2/Neu Positive Progesterone Receptor Negative Recurrent Breast Carcinoma Stage IV Breast Cancer Less << Phase 2 Recruiting February 2020 United States, Illinois ... More >> Northwestern University Recruiting Chicago, Illinois, United States, 60611 Contact: Cesar A. Santa-Maria    312-695-4520    cesar.santa-maria@northwestern.edu    Principal Investigator: Cesar A. Santa-Maria, MD          Northwestern Lake Forest Hospital Recruiting Lake Forest, Illinois, United States, 60045 Contact: Valerie Nelson, MD    847-582-2134       Principal Investigator: Valerie Nelson, MD          United States, Texas Houston Methodist Hospital/Houston Methodist Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Jenny Chang, MD    713-441-9948       Principal Investigator: Jenny Chang, MD Less <<
NCT02513394 Breast Cancer Phase 3 Recruiting September 2025 -
NCT03531645 Malignant Neoplasms of Female ... More >>Genital Organs Less << Phase 2 Not yet recruiting February 2019 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Not yet recruiting Houston, Texas, United States, 77030 Contact       aajazaeri@mdanderson.org Less <<
NCT03498378 Head and Neck Squamous Cell Ca... More >>rcinoma Less << Phase 1 Recruiting January 2022 United States, California ... More >> UC San Diego Moores Cancer Center Recruiting La Jolla, California, United States, 92093 Contact: Kathryn Gold, MD Less <<
NCT02255461 Childhood Choroid Plexus Tumor... More >> Childhood Ependymoblastoma Childhood Grade III Meningioma Childhood High-grade Cerebellar Astrocytoma Childhood High-grade Cerebral Astrocytoma Childhood Medulloepithelioma Recurrent Childhood Anaplastic Astrocytoma Recurrent Childhood Anaplastic Oligoastrocytoma Recurrent Childhood Anaplastic Oligodendroglioma Recurrent Childhood Brain Stem Glioma Recurrent Childhood Cerebellar Astrocytoma Recurrent Childhood Cerebral Astrocytoma Recurrent Childhood Giant Cell Glioblastoma Recurrent Childhood Glioblastoma Recurrent Childhood Gliomatosis Cerebri Recurrent Childhood Gliosarcoma Recurrent Childhood Medulloblastoma Recurrent Childhood Pineoblastoma Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor Less << Phase 1 Recruiting December 31, 2018 United States, California ... More >> Childrens Hospital Los Angeles Recruiting Los Angeles, California, United States, 90027 Contact: Girish Dhall    323-361-4629    gdhall@chla.usc.edu    Principal Investigator: Girish Dhall          Lucile Packard Children Hospital Stanford University Recruiting Palo Alto, California, United States, 94304 Contact: Paul G. Fisher    650-721-5889    pfisher@stanford.edu    Principal Investigator: Paul G. Fisher          United States, District of Columbia Childrens National Medical Center Recruiting Washington, District of Columbia, United States, 20010-2970 Contact: Eugene Hwang, MD    202-476-5046    ehwang@childrensnational.org    Principal Investigator: Lindsay B Kilburn, MD          Sub-Investigator: Roger Packer, MD          Sub-Investigator: Brain Rood, MD          Sub-Investigator: Eugene Hwang, MD          United States, Illinois Lurie Childrens Hospital-Chicago Recruiting Chicago, Illinois, United States, 60614 Contact: Stewart Goldman    312-227-4874    sgoldman@luriechildrens.org    Principal Investigator: Stewart Goldman, MD          Sub-Investigator: Jason Fangusaro, MD          Sub-Investigator: Rishi Lulla, MD          Sub-Investigator: Natasha Pillay-Smiley, MD          United States, New York Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Ira Dunkel    212-639-2153    dunkeli@mskcc.org    Principal Investigator: Ira Dunkel          United States, North Carolina Duke University Medical Center Recruiting Durham, North Carolina, United States, 27710 Contact: David Van Mater, MD, PhD    919-684-3401    david.vanmater@duke.edu    Principal Investigator: David Van Mater          United States, Ohio Cincinnati Children Hospital Medical Center Recruiting Cincinnati, Ohio, United States, 45229 Contact: Maryam Fouladi    513-803-0721    maryam.fouladi@cchmc.org    Principal Investigator: Maryam Fouladi          United States, Pennsylvania Children Hospital of Pittsburgh of UPMC Recruiting Pittsburgh, Pennsylvania, United States, 15224 Contact: Ian Pollack    412-692-5881    Pollaci@chp.edu    Sub-Investigator: Ian Pollack, MD          Principal Investigator: A. Kim Ritchey, MD          United States, Tennessee St. Jude Children Research Hospital Recruiting Memphis, Tennessee, United States, 38105 Contact: Giles Robinson, MD    901-595-2907    giles.robinson@stjude.org    Principal Investigator: Zsila Sadighi, MD          Sub-Investigator: Amar Gajjar, MD          United States, Texas Texas Childrens Hospital Recruiting Houston, Texas, United States, 77030 Contact: Patricia M. Baxter, MD    832-824-4681    pabaxter@txch.org    Sub-Investigator: Murali M. Chintagumpala          Principal Investigator: Patricia Baxter          United States, Washington Seattle Children Hospital Recruiting Seattle, Washington, United States, 98105 Contact: Sarah Leary    206-987-2106    sarah.leary@seattlechildrens.org    Principal Investigator: Sarah Leary Less <<
NCT03478514 Mantle Cell Lymphoma ... More >> B Cell Lymphoma Less << Phase 2 Recruiting December 2022 United States, New York ... More >> Weill Cornell Medical College Recruiting New York, New York, United States, 10065 Contact: Peter Martin          United States, Ohio Ohio State University Recruiting Columbus, Ohio, United States, 43210 Contact: Kami Maddocks Less <<
NCT01209598 - Completed - -
NCT03560856 Breast Cancer ... More >> HR+/HER2-negative Breast Cancer Metastasis Less << Phase 2 Not yet recruiting June 1, 2022 -
NCT03242382 Soft-tissue Sarcoma|Osteosarco... More >>ma|Chordoma Less << PHASE2 RECRUITING 2024-09-30 Hospital de la Santa Creu i Sa... More >>nt Pau, Barcelona, Spain|Hospital Universitari Germans Trias i Pujol, Barcelona, Spain|Institut Català d'Oncología l'Hospitalet, Barcelona, Spain|Complejo Asistencial Universitario de León, León, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital General Universitario Gregorio Mara?on, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Fundación Jimenez Diaz, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Hospital Universitari Son Espases, Palma De Mallorca, Spain|Hospital Universitario de Canarias, Santa Cruz De Tenerife, Spain|Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain|Hospital Universitario Virgen del Rocío, Sevilla, 41013, Spain|Hospital Universitari i Politècnic La Fe, Valencia, Spain|Instituto Valenciano de Oncología, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain Less <<
NCT01953731 Healthy Phase 1 Completed - United States, Connecticut ... More >> Pfizer Investigational Site New Haven, Connecticut, United States, 06511 Less <<
NCT02131298 Healthy Phase 1 Completed - United States, Connecticut ... More >> Pfizer Investigational Site New Haven, Connecticut, United States, 06511 Less <<
NCT01209598 Sarcoma Lipos... More >>arcoma Less << Phase 2 Completed - United States, New York ... More >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Less <<
NCT02806050 Breast Cancer Phase 2 Active, not recruiting November 2019 Netherlands ... More >> University Medical Center Groningen Groningen, Netherlands, 9713 GZ Less <<
NCT03284957 Breast Cancer Phase 1 Phase 2 Recruiting October 21, 2020 United States, Massachusetts ... More >> Investigational Site Number 8400002 Recruiting Boston, Massachusetts, United States, 02114 United States, New York Investigational Site Number 8400003 Recruiting New York, New York, United States, 10065 United States, Washington Investigational Site Number 8400001 Recruiting Seattle, Washington, United States, 98109 France Investigational Site Number 2500001 Recruiting Nantes, France, 44093 Less <<
NCT03389477 Head and Neck Squamous Cell Ca... More >>rcinoma Less << Phase 2 Recruiting June 30, 2026 United States, Missouri ... More >> Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Douglas R Adkins, M.D.    314-362-4471    dadkins@wustl.edu    Principal Investigator: Douglas R Adkins, M.D.          Sub-Investigator: Olivia Aranha, M.D.          Sub-Investigator: Mackenzie Daly, M.D.          Sub-Investigator: Hiram Gay, M.D.          Sub-Investigator: Ryan Jackson, M.D.          Sub-Investigator: Peter Oppelt, M.D.          Sub-Investigator: Randal Paniello, M.D.          Sub-Investigator: Patrik Pipkorn, M.D.          Sub-Investigator: Jason Rich, M.D.          Sub-Investigator: Wade Thorstad, M.D.          Sub-Investigator: Jose Zevallos, M.D., MPH Less <<
NCT02384239 Metastatic Breast Cancer ... More >> Hormone Receptor Positive Less << Phase 2 Recruiting August 2020 United States, California ... More >> UCSF Helen Diller Family Comprehensive Cancer Center Recruiting San Francisco, California, United States, 94143 Contact: Amy DeLuca    415-353-7288    Amy.DeLuca@ucsf.edu    Contact: Ivy Wong    415-353-7873    Ivy.Wong@ucsf.edu    Principal Investigator: Hope Rugo, M.D.          United States, District of Columbia Georgetown University Recruiting Washington, District of Columbia, United States, 20007 Contact: Nellie Novielli    202-784-3923    noviella@georgetown.edu    Contact: Julie Castle    202-687-2209    bickmorj@georgetown.edu    Principal Investigator: Claudine Issacs, MD          United States, Illinois University of Chicago Recruiting Chicago, Illinois, United States, 60637 Contact: Nana Owusu    773-702-2065    nowusu@medicine.bsd.uchicago.edu    Contact: Glenna Smith    773-834-2143    gsmith6@bsd.uchicago.edu    Principal Investigator: Rita Nanda, MD          United States, Indiana Indiana University Recruiting Indianapolis, Indiana, United States, 46202 Contact: Robbie Comito    317-274-0935    rcomito@iupui.edu    Principal Investigator: Anna Maria Storniolo, MD          United States, Maryland Johns Hopkins University Recruiting Baltimore, Maryland, United States, 21287 Contact: Bridget Walsh    410-502-3613    bwalsh9@jhmi.edu    Principal Investigator: Vered Stearns, MD          United States, Massachusetts Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Lauren Fisher    617-632-4321    lfisher7@partners.org    Contact: Nicole Ryabin    617-632-6767    Nicole_Ryabin@dfci.harvard.edu    Principal Investigator: Erica Mayer, MD          United States, Michigan University of Michigan Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Richelle Pelton    734-763-2960    peltonr@med.umich.edu    Principal Investigator: Catherine Van Poznak, MD          United States, Tennessee Vanderbilt University Recruiting Nashville, Tennessee, United States, 37240 Contact: Mikala Barnes    615-875-0072    mikala.barnes@vanderbilt.edu    Contact: Kathleen Sanders    615-343-4091    kathleen.sanders@Vanderbilt.Edu    Principal Investigator: Ingrid Mayer, MD          United States, Texas Baylor College of Medicine Recruiting Houston, Texas, United States, 77030 Contact: Claudette Foreman    713-798-7315    claudette.foreman@bcm.edu    Contact: Anne Pavlick    713-798-7814    anne.pavlick@bcm.edu    Principal Investigator: Polly Niravath, MD Less <<
NCT02499120 Squamous Cell Carcinoma of the... More >> Head and Neck (SCCHN) Less << Phase 2 Active, not recruiting June 21, 2019 -
NCT03170206 Lung Cancer Phase 1 Phase 2 Recruiting March 31, 2024 United States, Massachusetts ... More >> Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Geoffrey Shapiro, MD, PhD    617-632-4942       Principal Investigator: Geoffrey Shapiro, MD          Massachusetts General Hospital Not yet recruiting Boston, Massachusetts, United States, 02215 Contact: Rebecca Heist, MD    617-726-1838       Principal Investigator: Rebecca Heist, MD Less <<
NCT03194373 Squamous Cell Carcinoma of the... More >> Head and Neck Less << Phase 2 Recruiting July 3, 2021 United States, Indiana ... More >> Indiana University Simon Cancer Center Recruiting Indianapolis, Indiana, United States, 46202 Contact: Anya Kjeldsen    317-278-0779    amkjelds@iu.edu    Principal Investigator: Greg Durm, MD          United States, Michigan University of Michigan Comprehensive Cancer Center Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Paul Swiecicki, M.D.    734-647-1017    pswiecic@umich.edu    Principal Investigator: Paul Swiecicki, M.D.          United States, Tennessee Vanderbilt University Not yet recruiting Nashville, Tennessee, United States, 37203 Principal Investigator: Michael Gibson, M.D. Less <<
NCT02311946 Healthy Phase 1 Completed - United States, Florida ... More >> MRA Clinical Research - Phase 1 Miami, Florida, United States, 33143 Miami Research Associates, LLC South Miami, Florida, United States, 33143 MRA Clinical Research, LLC South Miami, Florida, United States, 33143 Less <<
NCT03220191 Healthy Volunteer Phase 1 Completed - United States, Connecticut ... More >> Pfizer New Haven Clinical Research Unit New Haven, Connecticut, United States, 06511 Less <<
NCT03472573 Recurrent B Acute Lymphoblasti... More >>c Leukemia Refractory B Acute Lymphoblastic Leukemia Less << Phase 1 Recruiting November 2020 United States, Pennsylvania ... More >> Sidney Kimmel Cancer Center at Thomas Jefferson University Recruiting Philadelphia, Pennsylvania, United States, 19107 Contact: Margaret Kasner, MD    215-955-8874    margaret.kasner@jefferson.edu    Principal Investigator: Margaret Kasner, MD Less <<
NCT02022982 KRAS Mutant Non-Small Cell Lun... More >>g Cancer Solid Tumors Less << Phase 1 Phase 2 Active, not recruiting December 2020 United States, Massachusetts ... More >> Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 Less <<
NCT03065062 Lung Cancer Squamous Cell ... More >> Solid Tumors Head & Neck Cancer Pancreatic Cancer Less << Phase 1 Recruiting January 2023 United States, Massachusetts ... More >> Massachusetts General Hospital Not yet recruiting Boston, Massachusetts, United States, 02114 Contact: Rebecca Heist, MD    617-726-1838       Principal Investigator: Rebecca Heist, MD          Beth Israel Deaconess Medical Center Not yet recruiting Boston, Massachusetts, United States, 02115 Contact: James Mier, MD    617-667-0430       Principal Investigator: James Mier, MD          Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02115 Contact: Andrew Wolanski, NP    617-632-6623    awolanski@partners.org    Principal Investigator: Geoffrey Shapiro, MD Less <<
NCT02448771 Breast Cancer Stage IV ... More >> Unresectable Locally Advanced Invasive Breast Cancer Metastatic Invasive Breast Cancer Less << Phase 1 Phase 2 Active, not recruiting April 2022 United States, Massachusetts ... More >> Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 Less <<
NCT02334800 Healthy, Hepatic Insufficiency Phase 1 Completed - United States, Florida ... More >> Orlando Clinical Research Center Orlando, Florida, United States, 32809 Weston Diagnostics (Ultrasound Facility) Orlando, Florida, United States, 32825 Less <<
NCT03184090 Metastatic Breast Cancer Phase 2 Recruiting March 2019 Italy ... More >> Ospedale Antonio Perrino Not yet recruiting Brindisi, Italy Contact: Saverio Cinieri          Principal Investigator: Saverio Cinieri          Istituto Europeo di Oncologia Not yet recruiting Milan, Italy Contact: Giuseppe Curigliano          Principal Investigator: Giuseppe Curigliano          Azienda Sanitaria Universitaria Integrata di Udine Not yet recruiting Udine, Italy Contact: Allesandro Minisini          Principal Investigator: Allesandro Minisini          Spain ICO Badalona Recruiting Badalona, Barcelona, Spain Contact: Vanesa Quiroga          Principal Investigator: Vanesa Quiroga          ICO l'Hospitalet Recruiting L'Hospitalet de Llobregat, Barcelona, Spain, 08007 Contact: Miguel Gil          Principal Investigator: Miguel Gil          Clinico Universitario A Coruña Recruiting A Coruña, Spain Contact: Lourdes Calvo          Principal Investigator: Lourdes Calvo          Hospital del Mar Recruiting Barcelona, Spain, 08003 Contact: Joan Albanell          Principal Investigator: Joan Albanell          Hospital Reina Sofia Recruiting Cordoba, Spain Contact: Juan De La Haba          Principal Investigator: Juan De La Haba          Hospital de Leon Recruiting Leon, Spain Contact: Andrés Garcia-Palomo          Principal Investigator: Andres Garcia-Palomo          Hospital 12 de Octubre Recruiting Madrid, Spain Contact: Eva Ciruelos          Principal Investigator: Eva Ciruelos          Hospital Clinico San Carlos Recruiting Madrid, Spain Contact: Jose Angel Garcia-Saenz          Principal Investigator: Jose Angel Garcia-Saenz          Hospital La Paz Recruiting Madrid, Spain Contact: Enrique Espinosa          Principal Investigator: Enrique Espinosa          Hospital Virgen del Rocío Recruiting Sevilla, Spain Contact: Manuel Ruiz          Principal Investigator: Manuel Ruiz          Hospital Clinico Universitario de Valencia Recruiting Valencia, Spain Contact: Begoña Bermejo          Principal Investigator: Begoña Bermejo          Hospital Universitari i Politecnic La Fe Recruiting Valencia, Spain Contact: Ana Santaballa          Principal Investigator: Ana Santaballa          Hospital Miguel Servet Recruiting Zaragoza, Spain Contact: Antonio Antón          Principal Investigator: Antonio Antón Less <<
NCT02334800 - Completed - -
NCT01864746 Breast Cancer ... More >> Hormonreceptor Positive Her2-normal Postneoadjuvant Treatment With CDK 4/6 Inhibitor CPS-EG Score Less << Phase 3 Active, not recruiting November 2023 United States, Pennsylvania ... More >> NSABP Foundation Pittsburgh, Pennsylvania, United States, 15212 Australia, New South Wales Contact: Australia and New Zealand Breast Cancer Trials Group Newcastle, New South Wales, Australia, PO Box 155 Austria Contact: Austrian Breast & Colorectal Cancer Study Group Vienna, Austria, 1090 Canada Contact: NSABP Foundation Multiple Locations, Canada France Contact: UNICANCER Paris, France, 75654 Germany Contact: German Breast Group Neu-Isenburg, Germany, 63263 Ireland Contact: Cancer Trials Ireland Dublin, Ireland, 2 Japan Contact: Japan Breast Cancer Research Group Tokyo, Japan, 103-0016 Korea, Republic of Contact: Korea Cancer Study Group Seoul, Korea, Republic of, 138-736 Spain GEICAM San Sebastián de los Reyes, Spain, 28703 United Kingdom Contact: Institute of Cancer Research London, United Kingdom, SW7 3RP Less <<
NCT03454035 Tumor, Solid ... More >>Pancreatic Cancer Less << Phase 1 Recruiting October 24, 2023 United States, North Carolina ... More >> Lineberger Comprehensive Cancer Center Recruiting Chapel Hill, North Carolina, United States, 27599 Less <<
NCT03132454 Hematopoietic/Lymphoid Cancer ... More >> Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Less << Phase 1 Recruiting July 2021 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact       tkadia@mdanderson.org Less <<
NCT02334527 Metastatic Urothelial Carcinom... More >>a (UC) Less << PHASE2 TERMINATED 2017-09-28 University of Michigan, Ann Ar... More >>bor, Michigan, 48109, United States|North Carolina Cancer Hospital (UNC), Chapel Hill, North Carolina, 27599, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, 37232, United States Less <<
NCT03285568 Metastatic Breast Cancer|Advan... More >>ced Breast Cancer|Estrogen Receptor-positive Breast Cancer|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Less << COMPLETED 2016-12-30 -
NCT03530696 HER2-positive Breast Cancer ... More >> Breast Cancer Breast Cancer Stage Recurrent Breast Cancer Metastatic Breast Cancer HER2 Positive Breast Carcinoma Less << Phase 2 Not yet recruiting August 1, 2022 -
NCT02334527 Metastatic Urothelial Carcinom... More >>a (UC) Less << PHASE2 TERMINATED 2017-09-28 University of Michigan, Ann Ar... More >>bor, Michigan, 48109, United States|North Carolina Cancer Hospital (UNC), Chapel Hill, North Carolina, 27599, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, 37232, United States Less <<
NCT02738866 Metastatic Breast Cancer Phase 2 Recruiting January 2020 United States, District of Col... More >>umbia Kimmel Cancer Center at Johns Hopkins at Sibley Memorial Hospital Recruiting Washington, District of Columbia, United States, 20016 Contact: Hopkins Breast Trials    410-955-8804    HopkinsBreastTrials@jhmi.edu    Principal Investigator: Raquel Nunes, MD          United States, Maryland Anne Arundel Health System Research Institute, Inc. Recruiting Annapolis, Maryland, United States, 21401 Principal Investigator: Jeanine Werner, MD          Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Recruiting Baltimore, Maryland, United States, 21287 Contact: Hopkins Breast Trials    410-955-8804    HopkinsBreastTrials@jhmi.edu    Principal Investigator: Vered Stearns, M.D.          United States, Pennsylvania Allegheny Health Network (AHN) - Allegheny General Hospital ONLY Recruiting Pittsburgh, Pennsylvania, United States, 15212 Principal Investigator: Antonios Christou, MD          Reading Hospital - McGlinn Cancer Institute Recruiting West Reading, Pennsylvania, United States, 19611 Principal Investigator: Terrence Cescon,, MD Less <<
NCT02896335 Metastatic Malignant Neoplasm ... More >>to Brain Less << Phase 2 Recruiting August 2022 United States, Massachusetts ... More >> Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Priscilla Brastianos, MD    617-724-8770    PBRASTIANOS@mgh.harvard.edu    Principal Investigator: Priscilla Brastianos, MD          Dana Farber Cancer Institute Not yet recruiting Boston, Massachusetts, United States, 02215 Contact: Eudocia K. Lee, MD    617-632-2166       Principal Investigator: Eudocia Lee, MD Less <<
NCT03454919 Melanoma PHASE2 UNKNOWN 2020-06-30 -
NCT02600923 Advanced Breast Cancer Female Phase 3 Recruiting March 29, 2019 Argentina ... More >> Instituto de Oncologia de Rosario Active, not recruiting Rosario, Santa FE, Argentina, S2000KZE Sanatorio Guemes Active, not recruiting Caba, Argentina, C1180AAX Hospital Italiano de Buenos Aires Active, not recruiting Caba, Argentina, C1181ACH Hospital Britanico de Buenos Aires Active, not recruiting Caba, Argentina, C1280AEB Instituto Medico Especializado Alexander Fleming Active, not recruiting Caba, Argentina, C1426ANZ Instituto de Cardiologia y Cirugia Cardiovascular Active, not recruiting Santa Fe, Argentina, S3000EPV ISIS Centro Especializado Active, not recruiting Santa Fe, Argentina, S3000FFU Brazil Hospital Da Cidade De Passo Fundo Recruiting Passo Fundo, RIO Grande DO SUL, Brazil, 99010-260 Hospital Sao Lucas da PUCRS / Uniao Brasileira de Educacao e Assistencia Active, not recruiting Porto Alegre, RIO Grande DO SUL, Brazil, 90610-000 Oncologia Rede D'Or S.A. Active, not recruiting Rio de Janeiro, Brazil, 22271-110 IDOR - Instituto D'Or em Pesquisa e Ensino Active, not recruiting Rio de Janeiro, Brazil, 22281-100 Sociedade Beneficente de Senhoras Hospital Sirio Libanes Recruiting Sao Paulo, Brazil, 01308-050 Clínica de Pesquisa e Centro de Estudos em Oncologia Ginecológica e Mamária Ltda Recruiting São Paulo, Brazil, 01317-000 Colombia Instituto de Cancerologia S.A. Active, not recruiting Medellin, Antioquia, Colombia, 050034 Oncomedica S.A. Active, not recruiting Monteria, Cordoba, Colombia, 230003 Administradora Country Active, not recruiting Bogota, Distrito Capital, Colombia, 11001000 Oncology Center Active, not recruiting Bogota, Distrito Capital, Colombia, 110221162 Imagenes Diagnosticas Active, not recruiting Pereira, Risaralda, Colombia, 660001 ONCOLOGOS DEL OCCIDENTE S.A.S Sede Pereira Clinica de Alta Tecnologia Maraya Active, not recruiting Pereira, Risaralda, Colombia, 660001 Mexico Fucam A.C. Active, not recruiting Coyoacan, D.f., Mexico, 04890 Instituto Nacional de Cancerologia Active, not recruiting Tlalpan, D.f., Mexico, 14080 Hospital Maria Auxiliadora Active, not recruiting Guadalajara, Jalisco, Mexico, 44540 Clinica de Especialidades Medicas Intepro, ONCE Oncologia Especializada Active, not recruiting Zapopan, Jalisco, Mexico, 45030 Hospital Universitario Dr. Jose Eleuterio Gonzalez Active, not recruiting Monterrey, Nuevo LEON, Mexico, 64460 Less <<
NCT02668666 Hormone Receptor Positive Mali... More >>gnant Neoplasm of Breast Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Estrogen Receptor Positive Breast Cancer Progesterone Receptor Positive Tumor Metastatic Breast Cancer Less << Phase 2 Recruiting June 2019 United States, Illinois ... More >> University of Illinois Cancer Center Recruiting Chicago, Illinois, United States, 60612 Contact: Oana Danciu, M.D.          Contact: Joanna Hill    312-996-9272    joanhill@uic.edu    United States, Michigan Michigan State University Recruiting Lansing, Michigan, United States, 48910 Contact: Karen Luellen    517-975-9534    Karen.Luellen@hc.msu.eduu.edu    Principal Investigator: Deimante Tamkus, M.D.          United States, Minnesota University of Minnesota Recruiting Minneapolis, Minnesota, United States, 55455 Contact: Erin Zielinski    612-624-0937    eezielin@umn.edu    Principal Investigator: Anne Blaes, MD          United States, Nebraska University of Nebraska Medical Center Recruiting Omaha, Nebraska, United States, 68198 Contact: Jennifer Messick    402-321-1911    jennifer.messick@unmc.edu    Principal Investigator: Pavan Kumar Tandra, MD          United States, Pennsylvania Penn State Cancer Institute Recruiting Hershey, Pennsylvania, United States, 17033 Contact: Christina Rodriquez    717-531-5364    crodriguez1@hmc.psu.edu    Principal Investigator: Cristina Truica, MD          Penn State Cancer Institute Recruiting Hershey, Pennsylvania, United States, 17033 Contact: Sean Fleming    717-531-5364    sfleming1@pennstatehealth.psu.edu    Principal Investigator: Cristina Truica, MD          United States, Wisconsin University of Wisconsin Recruiting Madison, Wisconsin, United States, 53705 Contact: Cancer Connect    608-262-5223    cancerconnect@uwcarbone.wisc.edu    Principal Investigator: Kari Wisinski, MD Less <<
NCT03439735 Breast Cancer Phase 2 Recruiting July 1, 2022 United States, Maryland ... More >> Johns Hopkins University Recruiting Baltimore, Maryland, United States, 21287 Contact: Hopkins Breast Trials    410-614-1361    hopkinsbreasttrials@jhmi.edu    Contact: Johns Hopkins Clinical Research Office    410-955-8866    JHCCCRO@jhmi.edu Less <<
NCT02530320 Oligodendroglioma|Oligoastrocy... More >>toma Less << PHASE2 COMPLETED 2025-03-20 Hospital Insular de Canarias, ... More >>Las Palmas de Gran Canaria, Las Palmas, Spain|Hospital Son Espases, Palma de Mallorca, Mallorca, Spain|Consorcio Hospitalario Provincial de Castellón, Castello de la Plana, Valencia, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|ICO Hospitalet, Barcelona, Spain|Hospital de León, León, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Regional de Málaga, Málaga, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Universitario y Politécnico La Fe, Valencia, Spain Less <<
NCT03535506 DCIS PHASE2 TERMINATED 2023-12-06 MedStar Georgetown University ... More >>Hospital, Washington, District of Columbia, 20007, United States|Medstar Washington Hospital Center, Washington, District of Columbia, 20010, United States Less <<
NCT02501902 Metastatic Pancreatic Ductal A... More >>denocarcinoma Less << Phase 1 Recruiting December 27, 2018 United States, Arizona ... More >> Scottsdale Healthcare Hospitals DBA HonorHealth Active, not recruiting Scottsdale, Arizona, United States, 85258 Virginia G. Piper Cancer Pharmacy Active, not recruiting Scottsdale, Arizona, United States, 85258 United States, California UCSD Medical Center - Encinitas Active, not recruiting Encinitas, California, United States, 92024 UC San Diego Medical Center - La Jolla (Thornton Hospital) Active, not recruiting La Jolla, California, United States, 92037-0845 UC San Diego Moores Cancer Center - Investigational Drug Services Active, not recruiting La Jolla, California, United States, 92037-0845 UC San Diego Moores Cancer Center Active, not recruiting La Jolla, California, United States, 92093 UC San Diego Medical Center - Hillcrest Active, not recruiting San Diego, California, United States, 92103 UCSD Medical Center - Vista Active, not recruiting Vista, California, United States, 92081 United States, Colorado Drug Shipment Address: Anschutz Cancer Pavilion Active, not recruiting Aurora, Colorado, United States, 80045 University of Colorado Cancer Center Active, not recruiting Aurora, Colorado, United States, 80045 University of Colorado Denver, CTO (CTRC) Active, not recruiting Aurora, Colorado, United States, 80045 University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP) Active, not recruiting Aurora, Colorado, United States, 80045 University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP) Active, not recruiting Aurora, Colorado, United States, 80045 United States, Maryland The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Active, not recruiting Baltimore, Maryland, United States, 21231-1000 United States, Massachusetts Beth Israel Deaconess Medical Center Active, not recruiting Boston, Massachusetts, United States, 02215 United States, Missouri Siteman Cancer Center - West County Active, not recruiting Creve Coeur, Missouri, United States, 63141 Barnes-Jewish Hospital Active, not recruiting Saint Louis, Missouri, United States, 63110 Washington University Infusion Center Pharmacy Active, not recruiting Saint Louis, Missouri, United States, 63110 Washington University School of Medicine Active, not recruiting Saint Louis, Missouri, United States, 63110 Siteman Cancer Center - South County Active, not recruiting Saint Louis, Missouri, United States, 63129 Siteman Cancer Center Active, not recruiting Saint Peters, Missouri, United States, 63376 United States, Utah University of Utah, Huntsman Cancer Hospital Active, not recruiting Salt Lake City, Utah, United States, 84112 University of Utah, Huntsman Cancer Institute Active, not recruiting Salt Lake City, Utah, United States, 84112 Spain Hospital Universitario de Fuenlabrada. Unidad de Farmacia (Only Drug Shipment) Recruiting Fuenlabrada, Madrid, Spain, 28942 Hospital Universitario Fuenlabrada Recruiting Fuenlabrada, Madrid, Spain, 28942 Hospital Universitari Vall D'Hebron Active, not recruiting Barcelona, Spain, 08035 Hospital Universitario 12 de Octubre Servicio de Farmacia Recruiting Madrid, Spain, 28041 Hospital Universitario 12 de Octubre Recruiting Madrid, Spain, 28041 Less <<
NCT03054363 Breast Cancer Phase 1 Phase 2 Recruiting October 2020 United States, Arizona ... More >> University of Arizona Recruiting Tucson, Arizona, United States, 85724 Contact: Dana Lewallen    520-626-2175    DLewallen@uacc.arizona.edu    Principal Investigator: Pavani Chalasani          United States, Colorado University of Colorado Denver Recruiting Aurora, Colorado, United States, 80045 Contact: Tiffany Colvin    720-848-0664    tiffany.colvin@ucdenver.edu    Principal Investigator: Elena Shagisultanova, MD, PhD          United States, Illinois Northwestern University Recruiting Chicago, Illinois, United States, 60611 Contact: Peggy Gilbertsen    312-695-1102    cancertrials@northwestern.edu    Principal Investigator: William Gradishar          United States, New Mexico New Mexico Cancer Care Alliance Recruiting Albuquerque, New Mexico, United States, 87131 Contact: Karwyn Gustafson    505-925-0380    KSGustafson@salud.unm.edu    Principal Investigator: Ursa Brown-Glaberman          United States, New York Stony Brook University Recruiting Stony Brook, New York, United States, 11794 Contact: Pushpa Talanki    631-638-0815    Pushpa.talanki@stonybrookmedicine.edu    Principal Investigator: Alison Stopeck          United States, Texas University of Texas Health Science Center San Antonio Recruiting San Antonio, Texas, United States, 78229 Contact: CTRC    210-450-5798    CTRCReferral@uthscsa.edu    Principal Investigator: Andrew Brenner Less <<
NCT03065621 Breast Cancer Female PHASE2 COMPLETED 2023-02-01 Institut Jules Bordet, Anderle... More >>cht, 1070, Belgium|CHU Brugmann, Brussels, 1090, Belgium|CHU Saint-Luc, Brussels, 1200, Belgium|UZ Leuven Gasthuisberg, Leuven, 3000, Belgium|CHU UCL Namur Sainte-Elisabeth, Namur, 5000, Belgium Less <<
NCT03123744 Cancer, Advanced Phase 2 Withdrawn(No study funding ava... More >>ilable.) Less << February 1, 2024 United States, California ... More >> UCSD Moores Cancer Center La Jolla, California, United States, 92093 Less <<
NCT03446157 Cancer of the Colon ... More >> Colon Cancer Colon Neoplasms Colonic Cancer Neoplasms, Colonic Less << Phase 2 Recruiting July 13, 2023 United States, North Carolina ... More >> Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill Recruiting Chapel Hill, North Carolina, United States, 27599-7295 Contact: Clinical Trials Office - Lineberger Comprehensive Cancer Cente    877-668-0683       Sub-Investigator: Cheryl Carlson, MD          Sub-Investigator: Autumn McRee, MD          Sub-Investigator: Hanna Sanoff, MD          Sub-Investigator: Tammy Triglianos, RN, NP Less <<
NCT02806648 Pancreatic Neuroendocrine Canc... More >>er Less << PHASE2 COMPLETED 2025-01-18 H.U.C de Asturias, Oviedo, Ast... More >>urias, Spain|ICO, L'Hospitalet de Llobregat, Barcelona, Spain|C. H. de Navarra, Pamplona, Navarra, Spain|H. Vall d′Hebron, Barcelona, Spain|H. Castellon, Castelló, 12002, Spain|H U Ramón y Cajal, Madrid, Spain|H. 12 Octubre, Madrid, Spain|H.U.La Paz, Madrid, Spain|H.U.Virgen del Rocio, Sevilla, Spain Less <<
NCT02310243 Acute Myeloid Leukemia|Acute L... More >>ymphoblastic Leukemia Less << PHASE1|PHASE2 UNKNOWN 2025-07-19 Klinikum Augsburg, Augsburg, 8... More >>6156, Germany|Helios Klinikum Bad Saarow, Bad Saarow, 15526, Germany|Charité Campus Benjamin Franklin, Berlin, 12200, Germany|Vivantes Klinikum Neuk?lln, Berlin, 12351, Germany|Charité Campus Virchow-Klinikum, Berlin, 13353, Germany|Universit?tsklinikum Bonn, Bonn, 53105, Germany|St?dtisches Klinikum Braunschweig gGmbH, Braunschweig, 38114, Germany|Universit?tsklinikum Düsseldorf, Düsseldorf, 40225, Germany|Kliniken Essen Süd, Ev. Krankenhaus Essen-Werden gGmbH, Essen, 45239, Germany|Malteser Krankenhaus St. Franziskus-Hospital, Flensburg, 24939, Germany|Universit?tsklinikum Freiburg, Freiburg, 791016, Germany|MVZ Osthessen, Fulda, 36043, Germany|Universit?tsklinikum Giessen, Giessen, 35392, Germany|Universit?tsklinikum Hamburg-Eppendorf, Hamburg, 20246, Germany|Medizinische Hochschule Hannover, Hannover, 30625, Germany|Universit?tsklinikum Heidelberg, Heidelberg, 69120, Germany|St?dtisches Klinikum Karlsruhe gGmbH, Karlsruhe, 76133, Germany|Universit?tsklinikum Schleswig-Holstein Campus Kiel, Kiel, 24116, Germany|Caritas-Krankenhaus Lebach, Lebach, 66822, Germany|Uni-Klinikum der Otto-von-Guericke-Universit?t, Magdeburg, 39120, Germany|Universit?tsmedizin der Johannes Gutenberg-Universit?t, Mainz, 55131, Germany|Pius Hospital Oldenburg, Oldenburg, 26121, Germany|Medizinische Universit?tsklinik Tübingen, Tübingen, 72076, Germany|University Hospital of Ulm, Ulm, 89081, Germany Less <<
NCT04318223 Metastatic Breast Cancer|Local... More >>ly Advanced Breast Cancer Less << PHASE2 UNKNOWN 2023-07-31 Nuovo ospedale di Prato - S. S... More >>tefano, Prato, Firenze, 59100, Italy|Ospedale Civile S. Giovanni di Dio, Frattamaggiore, Napoli, 80027, Italy|Centro di Riferimento oncologico, Aviano, Pordenone, 33081, Italy|Fondazione del Piemonte per l'Oncologia, Candiolo, Torino, 10060, Italy|Ospedale Sacro Cuore di Gesù Fatebenefratelli, Benevento, 82100, Italy|A.O. Osp. Riuniti - ASST PAPA GIOVANNI 23, Bergamo, 24127, Italy|Ospedale di Brindisi "Perrino", Brindisi, 72100, Italy|Ospedale Policnico San Martino, Genova, 16132, Italy|Ospedale Vito Fazzi, Lecce, 73100, Italy|Azienda Ospedaliera Papardo, Messina, 98158, Italy|Azienda Ospedaliero - Universitaria di Modena, Modena, 41125, Italy|A.O.U. Seconda Universita' degli Studi di Napoli, Napoli, 80131, Italy|Azienda Ospedaliera 'A. CARDARELLI', Napoli, 80131, Italy|Azienda Ospedaliera dei Colli - P.Monaldi, Napoli, 80131, Italy|Istituto Nazionale Tumori IRCCS Pascale, Napoli, 80131, Italy|Università degli Studi di Napoli "Federico II", Napoli, 80131, Italy|A.O.U. Pisana, Pisa, Italy|Istituto Nazionale Tumori Regina Elena (IRE, Roma, 00144, Italy|Ospedale Sandro Pertini, Roma, 00157, Italy Less <<
NCT03110744 Chordoma PHASE2 COMPLETED 2022-12-22 Universit?tsklinikum Essen, Es... More >>sen, 45147, Germany|National Center for Tumor Diseases, Heidelberg, 69120, Germany|Universit?tsklinikum Ulm, Ulm, 89081, Germany Less <<
NCT04992156 Metastatic Breast Cancer COMPLETED 2022-04-15 Fudan University Shanghai Canc... More >>er Center, Shanghai, China Less <<
NCT06076772 Metastatic Breast Cancer NOT_YET_RECRUITING 2025-12-26 Asmaa Imam Ahmed, Al Madīnah, ... More >>AL, 11564, Saudi Arabia Less <<
NCT05135104 Metastatic Breast Cancer UNKNOWN 2024-05-25 Asociatia Oncohelp - Centrul d... More >>e Oncologie Oncohelp, Timisoara, Timi?, 300239, Romania|Spitalul Clinic de Obstetric? ?i Ginecologie Filantropia, Bucuresti, 011171, Romania|Institutul Oncologic "Prof. Dr I. Chiricuta", Cluj-Napoca, 400015, Romania|Spitalul Clinic Jude?ean de Urgen?? Cluj-Napoca, Cluj-Napoca, 400349, Romania|Centrul de Oncologie "Sf. Nectarie", Craiova, 200746, Romania|Institutul Regional de Oncologie, Ia?i, 700483, Romania|Spitalul Clinic Jude?ean de Urgen?? Oradea, Oradea, 410469, Romania Less <<
NCT06338644 Hormone-receptor-positive Brea... More >>st Cancer|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Metastatic Breast Cancer Less << NOT_YET_RECRUITING 2026-09-01 -
NCT04247633 Breast Cancer PHASE2 UNKNOWN 2025-02-25 Samsung Medical Center, Seoul,... More >> 135-710, Korea, Republic of Less <<
NCT04439201 Advanced Lymphoma|Advanced Mal... More >>ignant Solid Neoplasm|Hematopoietic and Lymphoid Cell Neoplasm|Refractory Lymphoma|Refractory Malignant Solid Neoplasm Less << PHASE2 ACTIVE_NOT_RECRUITING 2025-12-31 ECOG-ACRIN Cancer Research Gro... More >>up, Philadelphia, Pennsylvania, 19103, United States Less <<
NCT04289974 Breast Cancer UNKNOWN 2025-04-22 Cancer Hospital, ChineseAMS, B... More >>eijing, Beijing, 100021, China Less <<
NCT05371275 COVID-19 PHASE2 WITHDRAWN 2025-12-22 Universit?tsklinikum Brandenbu... More >>rg an der Havel, Brandenburg an der Havel, 14770, Germany Less <<
NCT06003114 Breast Cancer COMPLETED 2024-02-22 Alberta Health Services, Edmon... More >>ton, Alberta, T5J 3E4, Canada Less <<
NCT03921866 HR+/HER2- Locally Advanced, Me... More >>tastatic Breast Cancer Less << COMPLETED 2021-03-04 Royal Cornwall Hospital, Truro... More >>, Cornwall, TR1 3LQ, United Kingdom|Brighton Sussex Cancer Centre, Brighton, BN2 5BB, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom|Guys and St Thomas' NHS Trust, London, SE1 9RT, United Kingdom|Maidstone Hospital, Maidstone, ME16 9QQ, United Kingdom|The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom|Newcastle Freeman Hospital, Newcastle upon Tyne, NE7 7DN, United Kingdom|Clatterbridge, Wirral, CH63 4JY, United Kingdom Less <<
NCT04109261 Breast Cancer COMPLETED 2019-09-01 Fernando Moreno, Madrid, 28040... More >>, Spain Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.23mL

0.45mL

0.22mL

11.17mL

2.23mL

1.12mL

22.34mL

4.47mL

2.23mL

References

 

Historical Records

Categories